An Open-Label, Single-Group Study to Evaluate the Efficacy and Safety of SPN-820 in Adults With Major Depressive Disorder
Latest Information Update: 21 Feb 2025
At a glance
- Drugs NV-5138 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Navitor Pharmaceuticals
Most Recent Events
- 17 Feb 2025 Status changed from recruiting to completed.
- 14 Nov 2024 Planned End Date changed from 15 Oct 2024 to 31 Dec 2024.
- 14 Nov 2024 Planned primary completion date changed from 15 Oct 2024 to 31 Dec 2024.